The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications: 1. Long and short bone extra-articular comminuted fracture 2. Long and short bones extra and intra articular defect /Gap or non-union, incapable of self-regeneration
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary safety endpoint: Absence of treatment-emergent appearance of safety issues
Timeframe: Throughout the post-intervention 12-month follow-up
Efficacy endpoint: Bone continuity
Timeframe: Starting 4-week follow-up and through to the end of the 12-month follow-up
Functional efficacy endpoint: Weight bearing ability
Timeframe: The test is performed at 3, 6 and 12 months post operation.